^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    Blenrep (belantamab mafodotin-blmf)

    i
    Other names: GSK2857916, J6M0-mcMMAF, GSK 2857916, GSK-2857916, GSK916, GSK-916, GSK 916
    Company:
    GSK, Pfizer
    Drug class:
    Microtubule inhibitor, BCMA-targeted antibody-drug conjugate
    Related drugs:
    4d
    BELAMI: A Multicenter Study of Belantamab Mafodotin and Mezigdomide in Patients With Relapsed Multiple Myeloma (clinicaltrials.gov)
    P1/2, N=44, Not yet recruiting, Centre Hospitalier Universitaire de Saint Etienne | Phase classification: P2 --> P1/2
    Phase classification
    |
    Blenrep (belantamab mafodotin-blmf) • mezigdomide (CC-92480)
    7d
    DREAMM8: Belantamab Mafodotin Plus Pomalidomide and Dexamethasone (Pd) Versus Bortezomib Plus Pd in Relapsed/Refractory Multiple Myeloma (clinicaltrials.gov)
    P3, N=302, Active, not recruiting, GlaxoSmithKline | Trial completion date: Oct 2029 --> Jun 2029
    Trial completion date
    |
    bortezomib • dexamethasone • pomalidomide • Blenrep (belantamab mafodotin-blmf)
    7d
    DREAMM 8: All Japanese Population: Belantamab Mafodotin Plus Pomalidomide and Dexamethasone (Pd) Versus Bortezomib Plus Pd in Relapsed/Refractory Multiple Myeloma (clinicaltrials.gov)
    P3, N=21, Active, not recruiting, GlaxoSmithKline | Trial completion date: Nov 2029 --> Jun 2029
    Trial completion date
    |
    bortezomib • dexamethasone • pomalidomide • Blenrep (belantamab mafodotin-blmf)
    7d
    BelaCarD: A phase I/II single arm study of combination Belantamab Mafodotin, Carfilzomib, Dexamethasone in patients with early relapsed multiple myeloma (ACTRN12620000490976)
    P1/2, N=140, Recruiting, Australasian Myeloma Research Consortium | Active, not recruiting --> Recruiting | N=68 --> 140
    Enrollment open • Enrollment change
    |
    carfilzomib • dexamethasone • Blenrep (belantamab mafodotin-blmf)
    10d
    GEM-BELACOMBOS: Study to Evaluate Efficacy and Safety of Belantamab-based Combinations for Relapsed Multiple Myeloma (clinicaltrials.gov)
    P=N/A, N=100, Not yet recruiting, PETHEMA Foundation
    New trial
    |
    B2M (Beta-2-microglobulin)
    |
    bortezomib • dexamethasone • pomalidomide • Blenrep (belantamab mafodotin-blmf)
    20d
    DREAMM-16: Study of Alternative and Approved Dosing Regimens of Belantamab Mafodotin, Bortezomib, and Dexamethasone (BVd) in Participants With Relapsed/Refractory Multiple Myeloma (clinicaltrials.gov)
    P2, N=120, Not yet recruiting, GlaxoSmithKline
    New P2 trial
    |
    bortezomib • dexamethasone • Blenrep (belantamab mafodotin-blmf)
    21d
    BELAMI: A Multicenter Study of Belantamab Mafodotin and Mezigdomide in Patients With Relapsed Multiple Myeloma (clinicaltrials.gov)
    P2, N=44, Not yet recruiting, Centre Hospitalier Universitaire de Saint Etienne
    New P2 trial
    |
    Blenrep (belantamab mafodotin-blmf) • mezigdomide (CC-92480)
    23d
    A Study of the Combination of Belantamab Mafodotin, Bortezomib, and Dexamethasone (BVd) in Participants With Multiple Myeloma and Moderate Hepatic Impairment (clinicaltrials.gov)
    P1, N=20, Not yet recruiting, GlaxoSmithKline
    New P1 trial
    |
    bortezomib • dexamethasone • Blenrep (belantamab mafodotin-blmf)
    1m
    BELI(E)VE: Combination Treatment of Belantamab Mafodotin and Venetoclax in Treatment of Relapsed and Refractory t(11;14) Multiple Myeloma (clinicaltrials.gov)
    P1/2, N=45, Recruiting, Universitätsklinikum Hamburg-Eppendorf | Trial completion date: Dec 2026 --> Dec 2028 | Trial primary completion date: Nov 2026 --> Apr 2027
    Trial completion date • Trial primary completion date
    |
    Chr t(11;14)
    |
    Venclexta (venetoclax) • Blenrep (belantamab mafodotin-blmf)
    1m
    Novel Combination of Belantamab Mafodotin and Elotuzumab to Enhance Therapeutic Efficacy in Multiple Myeloma (clinicaltrials.gov)
    P1/2, N=24, Active, not recruiting, Yale University | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    Empliciti (elotuzumab) • Blenrep (belantamab mafodotin-blmf)
    1m
    GEM-BELMA: Study of Belantamab Mafodotin in Combination With Kd for the Treatment of Relapsed Myeloma Patients, Refractory to Lenalidomide (clinicaltrials.gov)
    P1/2, N=60, Active, not recruiting, PETHEMA Foundation | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    lenalidomide • carfilzomib • dexamethasone • Blenrep (belantamab mafodotin-blmf)
    1m
    Phase 1/2a Study of Belantamab Mafodotin in Relapsed or Refractory AL Amyloidosis (clinicaltrials.gov)
    P1/2, N=37, Recruiting, University of Texas Southwestern Medical Center | Trial completion date: Sep 2026 --> Sep 2027 | Trial primary completion date: Mar 2026 --> Mar 2027
    Trial completion date • Trial primary completion date
    |
    Blenrep (belantamab mafodotin-blmf)